Strategic partnerships DiaCarta has recent and ongoing collaborations with Capstone Health Alliance, OncoAssure, AnchorDx, and Nonagen Bioscience, indicating a strong partner-first approach. This presents opportunities to align sales efforts with these networks to expand distribution, co-development, and integration of DiaCarta’s ultra-sensitive diagnostics into partner portfolios and procurement channels.

Cancer diagnostics focus The company specializes in liquid biopsy, cancer diagnosis, therapy identification, and prognosis monitoring. Target opportunities include hospitals and clinics expanding precision oncology programs, GPOs seeking novel oncology tools, and direct sales to labs implementing translational genomics to enhance patient stratification and monitoring.

Infectious disease tools DiaCarta’s experience with COVID-19 and Flu A&B panels and infectious disease assays suggests cross-sell potential into surveillance and monitoring programs, particularly in institutions prioritizing rapid, ultra-sensitive pathogen detection alongside oncology offerings.

Growing footprint With a lean team and revenues in the mid-range for a biotech firm, DiaCarta is in a phase where strategic partnerships, licensing, and contract R&D engagements can scale revenue without heavy fixed-cost expansion. This is favorable for channel or OEM-style sales models and joint development deals.

Global collaboration Active cross-border partnerships (Ireland, China, Thailand) indicate receptiveness to international market entries and regulatory navigation support. Sales opportunities exist in global markets via licensing, distribution agreements, or co-branded products that leverage DiaCarta’s technology and regional partners’ networks.